Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash?

Core Insights - Pfizer is transitioning from a peak revenue era driven by the coronavirus vaccine, which generated over $37 billion in 2022, to a new growth phase through strategic acquisitions and product development [1][2][4]. Group 1: Revenue and Market Position - The demand for coronavirus vaccines has declined, and Pfizer is facing the loss of exclusivity for older blockbuster drugs, impacting its revenue streams [2][4]. - Despite these challenges, Pfizer reported over $10 billion in revenue from recent product launches and acquisitions last year, up from $8.9 billion the previous year [10]. Group 2: Strategic Acquisitions - Pfizer's acquisition of Seagen has provided access to several commercialized drugs, including Padcev for bladder cancer, which has achieved blockbuster status with over $1 billion in annual revenue [6]. - The company has also acquired Metsera, focusing on developing weight loss drug candidates, which is a growing market expected to approach $100 billion by the end of the decade [8][9]. Group 3: Future Growth Potential - Pfizer is focusing on in-house research and development and aims to reinvest $500 million in R&D by the end of the year [10]. - The company is exploring monthly dosing for its weight loss drug candidate, which could differentiate it in a market currently dominated by weekly dosing options [9].